<p><strong>Pfizer Inc.</strong> (NYSE:PFE) shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of berobenatide, an investigational GLP-1 receptor agonist for weight management.</p>



<h2>Pfizer Berobenatide Update</h2>



<p>On Saturday, the company reported that the Phase 2b studies for berobenatide demonstrated a non-placebo-adjusted weight loss of 15.9% in participants.</p>



<p>The pivotal Phase 3 study is currently open for enrollment, which may further bolster Pfizer’s position in the obesity treatment market.</p>



<p>Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials.</p>



<p>The first clinical experience with the top weekly dose for berobenatide is were presented for the first time.</p>



<div>


<p>
<strong>
Read Also:

Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies
</strong>
</p>


</div>


<p>Results from a 32-week exploratory extension (Part B) of the Phase 2b VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9% with no plateau observed at 32 weeks on berobenatide (Week 60 of the overall study), in participants who escalated from placebo to 2.4 mg weekly berobenatide.</p>



<h2>Phase 3 Program Expands</h2>



<p>The VESPER-6 pivotal Phase 3 study investigating monthly maintenance dosing for berobenatide in obese adults is open for enrollment, as well as the SOLIS-1 Phase 2b study investigating weekly and monthly maintenance dosing of an ultra-long-acting amylin analog (PF’3945) as a monotherapy and in combination with berobenatide.</p>



<h2>FDA Expands HYMPAVZI Indication</h2>



<p>On Monday, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Pfizer’s HYMPAVZI (marstacimab-hncq) to include hemophilia A or B patients 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors.</p>



<p>HYMPAVZI is the first subcutaneous non-factor therapy available for pediatric patients with hemophilia B aged 6 to 11 years.</p>



<p><strong>PFE Stock Price Activity:</strong> Pfizer shares were down 1.3% at $25.70 at the time of publication on Monday, according to Benzinga Pro data.</p>



<div>


<p>
<strong>
Read Also:

Cramer's Lightning Round: Buy Reddit Slowly, Avoid Chasing 'Parabolic' Winners
</strong>
</p>


</div>


<p><em>Photo: Molly Woodward / Shutterstock</em></p>

<p>Pfizer reported Phase 2b data for its investigational obesity drug berobenatide, showing a 15.9% non-placebo-adjusted weight loss. The company plans to advance multiple Phase 3 studies in 2026 for chronic weight management and related comorbidities. Concurrently, the FDA expanded HYMPAVZI's indication for hemophilia patients. Despite these developments, Pfizer shares declined by approximately 1.3%.</p>

- Pfizer Inc. shares fell nearly 1% following the release of Phase 2b data for berobenatide, showing a 15.9% non-placebo-adjusted weight loss in participants.  
- The company is advancing 10 Phase 3 studies in 2026 to enhance its obesity treatment market position, with the pivotal VESPER-6 study now open for enrollment.  
- Additionally, the FDA approved an expanded indication for Pfizer’s HYMPAVZI therapy for hemophilia A or B in certain pediatric populations.

Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study